Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150664 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
A Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Compass Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 7
- Study locations
NCT06150664: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Compass Therapeutics.
NCT06150664 is a Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Compass Therapeutics. The registered enrollment target is 73 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06150664, a Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Compass Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Primary Outcome
Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities
Conditions Studied
Interventions
- DRUG CTX-8371
Study Locations (7)
Florida
- D&H Cancer Research Center - Margate
- Florida Cancer Specialists - Lake Nona - Orlando
- Florida Cancer Specialists - Sarasota - Sarasota
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Roswell Park Cancer Institute - Buffalo
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT06150664 shows while recruiting
NCT06150664 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower).
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which CTX-8371 is the first listed.
NCT06150664 lists 7 locations in 4 states (Florida, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT06150664 about?
NCT06150664 is a clinical study titled "A Phase 1 of CTX-8371 in Patients With Advanced Malignancies". This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
What is the current status of trial NCT06150664?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2024-03-19. Estimated completion is 2027-05.
What conditions does trial NCT06150664 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hodgkin Lymphoma, Malignant Melanoma.
What interventions are being tested in trial NCT06150664?
The interventions under investigation include: CTX-8371 (DRUG).
Who is sponsoring clinical trial NCT06150664?
This trial is sponsored by Compass Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06150664 being conducted?
This trial has 7 study locations across Florida, Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06150664's enrollment target sits among peer trials
73 282nd of 454 higher than 172 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06247345 · 73 participants · Phase 1
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI